Further, the company's board has also recommended issuing one bonus equity share for one equity share held (1:1).

Moreover, the board also approved to enhance the limits applicable for extending loans, making investments and providing guarantees or security upto Rs 3,500 crore. The proposal (under Section 186) is subject to the approval of the shareholders/ members and statutory/regulatory and other approvals, as may be necessary.

Meanwhile, HGS has completed the sale of its healthcare services business to wholly-owned subsidiaries of Betaine BV, funds affiliated with Baring Private Equity Asia (BPEA), one of the largest private alternative investment firms in Asia.

The transaction was based on an enterprise value of $1,200 million, subject to closing adjustments, and resulted in inflows of $1,088 million.

As part of the divestment, HGS has transferred all client contracts and assets, including infrastructure related to the healthcare services business, to the Buyer. As part of the transition services agreement, the new healthcare organization will operate under the name "HGS Healthcare" for a period of up to 12 months from closing.

Post completion of the transaction, HGS will have around 18,800 employees and 34 delivery centers in the US, Canada, UK, Jamaica, Philippines, and India. The company's revenue run rate for Q4 FY2022 post divestment would be approximately $105-$110 million per quarter.

HGS is a global leader in optimizing the customer experience lifecycle, digital transformation, and business process management. It combines automation, analytics, and artificial intelligence with deep domain expertise focusing on digital customer experiences, back-office processing, contact centers, and HRO solutions.

On a consolidated basis, net profit of HGS rose 67.51% to Rs 136.50 crore on 18.76% rise in net sales to Rs 1582.56 crore in Q2 September 2021 over Q2 September 2020.

Shares of HGS hit a lower circuit of 20% at Rs 2855.45.